Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights
Loading...All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
Glutamate ionotropic receptor delta type subunit 1 (GRID1), also known as GluD1, is a postsynaptic membrane protein encoded by the GRID1 gene and a member of the ionotropic glutamate receptor family. Although GRID1 shares the characteristic modular architecture of ionotropic glutamate receptors, including an extracellular amino-terminal domain, a ligand-binding domain, three transmembrane helices, a re-entrant pore loop, and an intracellular C-terminal region, it is not primarily activated by glutamate in the manner of conventional AMPA, NMDA, or kainate receptors. Instead, GRID1 functions predominantly as a synaptic organizer and regulatory component at neuronal cell-cell contacts. A well-characterized role of GRID1 involves the formation of trans-synaptic adhesion complexes with presynaptic neurexins through cerebellin family proteins. In these NRXN-CBLN-GluD1 complexes, GRID1 contributes to synapse formation, maintenance, and organization by linking presynaptic adhesion machinery with postsynaptic signaling and structural components. GRID1 has also been implicated in the regulation of AMPA and NMDA receptor trafficking, localization, and synaptic abundance rather than in direct heteromeric assembly with these receptor subunits. Through these functions, GRID1 contributes to the organization and plasticity of excitatory and inhibitory synapses in multiple regions of the central nervous system. Its synaptic localization and protein-interaction network make GRID1 a relevant research target for studies of trans-synaptic organization, receptor trafficking, and neuronal connectivity.
GRID1 exerts its biological effects through heteromeric assembly with primary glutamate receptor subunits at postsynaptic membranes, a mechanism that modulates glutamate ligand binding stability and intracellular synaptic signal cascade activation efficiency. Unlike primary glutamate-binding receptor subunits, GRID1 cannot independently generate full ion flux responses and relies on receptor heterodimerization to tune synaptic signal magnitude; it recruits cytoplasmic signal mediators to assembled postsynaptic receptor complexes, uncoupling extracellular glutamate neurotransmitter recognition from intracellular neuronal transcription factor activation and sustaining balanced synaptic circuit response signals. This dual regulation modulates the intensity of glutamate-triggered postsynaptic responses after neurotransmitter release, fine-tuning local neuronal excitability and synaptic remodeling mediator secretion levels, while sustained abnormal GRID1-mediated receptor signaling drives dysregulated neuronal excitability and degenerative synaptic lesions. GRID1 participates in key physiological and pathological processes including postsynaptic glutamate transmission, neuronal circuit plasticity, neurotransmitter-mediated synaptic remodeling and chronic neurodegenerative disorders. Dysregulation of GRID1 expression or receptor heteromerization capacity is closely associated with disrupted synaptic balance and impaired neuronal circuit stability, making GRID1 a crucial research target for glutamate ionotropic receptor signaling, neuronal plasticity and neurodegenerative disease research.
Fig. 1 Trans-synaptic Neurexin-Cbln1-GRID1 (GluD1) scaffold regulates NMDA/AMPA receptor trafficking and autophagic flux under basal conditions; pathological PKC-mediated phosphorylation shifts LTD signaling and drives neuropathic allodynia.1
The biological functions of GRID1 are focused on ionotropic glutamate receptor heterodimerization, synaptic plasticity signal propagation and neuronal circuit balance:
Creative Biolabs offers high-purity GRID1 proteins through optimized heterologous expression systems. These products retain native conformational characteristics and glutamate receptor heteromeric binding activity, suitable for postsynaptic glutamate transmission research, receptor complex interaction detection, and small molecule neuroprotective compound screening for neurodegenerative disorder research. All GRID1 proteins undergo strict quality control, including purity analysis and biological activity validation to ensure biological function.
Not finding the membrane protein product you need? Contact us to start your one-stop custom service!
Creative Biolabs provides custom-engineered GRID1 stable cell lines, including overexpressing and knockdown models in excitatory neuronal and synaptic interneuron cell models. These cell lines are optimized for studying GRID1-mediated glutamate receptor heteromer assembly mechanisms, postsynaptic glutamate signal cascade dynamics, and neuroprotective compound sensitivity. Each cell line undergoes stringent validation, including stable expression detection and functional integrity verification.
Not finding the stable cell line product you need? Contact us to start your one-stop custom service!
High-specificity recombinant antibodies targeting GRID1 are developed via advanced antibody engineering technologies, with no cross-reactivity with other glutamate ionotropic receptor subunits. These antibodies are validated for multiple applications, including immunofluorescence for GRID1 postsynaptic membrane localization, Western blot for expression analysis, and co-immunoprecipitation for GRID1-glutamate receptor complex research, enabling precise analysis of GRID1 expression, subcellular localization and functional regulation.
Not finding the recombinant antibody product you need? Contact us to start your one-stop custom service!
Beyond catalog products, Creative Biolabs offers specialized custom services for GRID1 research:
GRID1 is a delta-type glutamate ionotropic receptor modulatory subunit that forms heteromeric complexes with primary glutamate receptors to modulate synaptic glutamate-driven excitatory signal amplitude, balance cortical neuronal circuit plasticity dynamics, and mediate postsynaptic remodeling upon neurotransmitter stimulation.
GRID1 is a core regulator of postsynaptic glutamate signaling and neuronal circuit homeostasis, and its dysregulation is associated with aberrant neuronal excitability and chronic synaptic degenerative lesions. It is a critical target for glutamate receptor and neurodegenerative disease research.
No, all GRID1 products and services are strictly for research use only, not intended for clinical diagnosis or treatment.
Offerings include GRID1 proteins (full-length, extracellular glutamate-binding domain variants), specific recombinant antibodies, and custom stable neuronal cell lines, supporting synaptic glutamate transmission and neurodegenerative disorder research.
GRID1 proteins are validated by glutamate receptor heteromeric binding assays and postsynaptic plasticity signal regulation verification to ensure native regulatory function in neuronal synaptic research.
